Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G9LP
|
|||
| Former ID |
DIB014177
|
|||
| Drug Name |
Neutralase
|
|||
| Synonyms |
Heparinase I, IBEX
Click to Show/Hide
|
|||
| Indication | Angiogenesis disorder [ICD-11: BE2Z; ICD-10: I00-I99] | Discontinued in Phase 3 | [1] | |
| Company |
IBEX Technologies Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Heparanase (HPSE) | Target Info | Modulator | [2] |
| KEGG Pathway | Glycosaminoglycan degradation | |||
| Metabolic pathways | ||||
| Proteoglycans in cancer | ||||
| Pathway Interaction Database | Syndecan-1-mediated signaling events | |||
| Reactome | HS-GAG degradation | |||
| WikiPathways | Glycosaminoglycan metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007559) | |||
| REF 2 | Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin. J Thromb Haemost. 2006 Mar;4(3):560-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.